Logo

Biogen to Acquire Nightstar Therapeutics for $800M

Share this

M&A

Biogen to Acquire Nightstar Therapeutics for $800M

Shots:

  • Biogen acquires Nightstar Therapeutics- in all stock transaction with its lead candidates NSR-REP1 & NSR-RPGR. Nightstar Therapeutics to receive $25.50 /share in cash for one day premium of 68% on closing of $15.16 making the total deal value $800M
  • The focus of an acquisition is to strengthen Biogen’s portfolio in ophthalmology. Biogen expected to complete the acquisition in H2’19
  • NST’s NSR-REP1 & NSR-RPGR are subretinal injections based on AVV vector used for the treatment of choroideremia (CHM) & X-linked retinitis pigmentosa (XLRP) respectively

Ref: Biogen | Image: Biogen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions